Engine Biosciences
AI-powered drug discovery company using network biology and combinatorial CRISPR screening to identify novel drug targets and synergistic drug combinations for cancer and other diseases.
Notes
Engine Biosciences is an AI-powered drug discovery company with operations in Singapore and Cambridge, Massachusetts. The company uses a proprietary platform that combines network biology, machine learning, and high-throughput combinatorial CRISPR screening to identify novel drug targets and synergistic drug combinations.
Engine's approach leverages the understanding that diseases are driven by networks of interacting genes, not single targets. By mapping these genetic networks and using AI to identify key nodes and combinations, the company aims to discover more effective therapeutic strategies, particularly for complex diseases like cancer.
The company has partnerships with pharmaceutical companies and academic institutions to advance its drug discovery programs.
Team
- Jeffrey Lu, Ph.D. - Co-founder & CEO
- Rene Quek, Ph.D. - Co-founder & Chief Business Officer
Additional Research Findings
- Founded in 2016
- Portfolio company of Polaris Partners
- Dual headquarters: Singapore and Cambridge, MA
- AI-driven drug discovery platform
- Combinatorial CRISPR screening technology
- Network biology approach
- Focus on cancer and other complex diseases
- Partnerships with pharma companies
- Raised significant venture funding
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |